CXCL1 and breast cancer: Bioinformatic analyses of microarray data, provided by the TCGA PanCancer collection, highlight the clinico-pathological relevance of our findings and reveal that expression of CXCL1 is prevalent in Triple-Negative (TN) BC, the molecular subtype with the highest CSC content and the worst clinical outcome (Honeth et al., 2008; Ma et al., 2014).